Nearly four years after its start, a phase III trial of Gamida Cell Ltd.'s ex vivo expanded cord blood candidate, omidubicel, for hematologic malignancies is fully enrolled, the company said.
The natural immune system has two lines of defense that complement each other. In response to an infection, a rapid but fairly unspecific and short-lived response by the innate immune system is followed by the precisely targeted attack of the B and T cells of the adaptive immune system, followed by immune memory that can last a lifetime
RSS
